AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.